Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
Titel:
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
Auteur:
Dimopoulos, Meletios A Richardson, Paul G Bahlis, Nizar J Grosicki, Sebastian Cavo, Michele Beksaç, Meral Legieć, Wojciech Liberati, Anna M Goldschmidt, Hartmut Belch, Andrew Magen, Hila Larocca, Alessandra Laubach, Jacob P Petrucci, Maria T Reece, Donna White, Darrell Mateos, María-Victoria Špička, Ivan Lazaroiu, Mihaela Berdeja, Jesús Kaufman, Jonathan L Jou, Ying-Ming Ganetsky, Alex Popa McKiver, Mihaela Lonial, Sagar Weisel, Katja